Plain-English translation of NCT06234007 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination approach for locally advanced rectal cancer that has spread to lymph nodes or nearby tissues. You would receive short-course radiation therapy followed by 6 cycles of a new anti-cancer medication called fruquintinib combined with adebrelimab and standard chemotherapy (CAPOX). After completing this treatment, you would have surgery to remove the cancer.
Rectal cancer that has spread to nearby lymph nodes or tissues is difficult to treat and often comes back. Researchers want to see if adding this new medication to radiation and chemotherapy can shrink tumors more effectively before surgery, which may improve your chances of long-term survival.
You likely qualify if…
You likely don't qualify if…
You would start with a screening period to confirm your eligibility. Then you would receive short-course radiation therapy, followed by 6 cycles of the medication combination given over several weeks. Before each treatment cycle, you would have blood tests, imaging scans, and physical exams to ensure you're tolerating the treatment safely. After completing all medication cycles, you would wait one week and then undergo surgery to remove the cancer. The study includes follow-up visits to monitor your safety and long-term health outcomes.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China